Deal watch: Biogen and Amicus to pursue genetically validated Parkinson's disease target

摘要

Biogen Idee has teamed up with Amicus Therapeutics to develop a new approach to Parkinson's disease based on targeting the lysosomal enzyme (3-glucocerebrosidase (GBA; also known as (3-glucosidase). Preclinical studies have shown that increasing the activity of GBA in the brain might prevent the aggregation of alpha-synuclein, which is a feature of a group of neurodegenerative disorders that includes Parkinson's disease and dementia with Lewy bodies (Proc. Natl Acad. Sri. USA 110, 3537-3542; 2013).